Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2018

Open Access 01-12-2018 | Research

Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP

Authors: Jasmine Peak, Ilias Goranitis, Ed Day, Alex Copello, Nick Freemantle, Emma Frew

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Login to get access

Abstract

Background

Economic evaluation normally requires information to be collected on outcome improvement using utility values. This is often not collected during the treatment of substance use disorders making cost-effectiveness evaluations of therapy difficult. One potential solution is the use of mapping to generate utility values from clinical measures. This study develops and evaluates mapping algorithms that could be used to predict the EuroQol-5D (EQ-5D-5 L) and the ICEpop CAPability measure for Adults (ICECAP-A) from the three commonly used clinical measures; the CORE-OM, the LDQ and the TOP measures.

Methods

Models were estimated using pilot trial data of heroin users in opiate substitution treatment. In the trial the EQ-5D-5 L, ICECAP-A, CORE-OM, LDQ and TOP were administered at baseline, three and twelve month time intervals. Mapping was conducted using estimation and validation datasets. The normal estimation dataset, which comprised of baseline sample data, used ordinary least squares (OLS) and tobit regression methods. Data from the baseline and three month time periods were combined to create a pooled estimation dataset. Cluster and mixed regression methods were used to map from this dataset. Predictive accuracy of the models was assessed using the root mean square error (RMSE) and the mean absolute error (MAE). Algorithms were validated using sample data from the follow-up time periods.

Results

Mapping algorithms can be used to predict the ICECAP-A and the EQ-5D-5 L in the context of opiate dependence. Although both measures can be predicted, the ICECAP-A was better predicted by the clinical measures. There were no advantages of pooling the data. There were 6 chosen mapping algorithms, which had MAE scores ranging from 0.100 to 0.138 and RMSE scores ranging from 0.134 to 0.178.

Conclusion

It is possible to predict the scores of the ICECAP-A and the EQ-5D-5 L with the use of mapping. In the context of opiate dependence, these algorithms provide the possibility of generating utility values from clinical measures and thus enabling economic evaluation of alternative therapy options.

Trial registration

ISRCTN22608399. Date of registration: 27/04/2012. Date of first randomisation: 14/08/2012.
Appendix
Available only for authorised users
Literature
1.
go back to reference Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester: Wiley; 2007. Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester: Wiley; 2007.
2.
go back to reference Coast J. Maximisation in extra-welfarism: a critique of the current position in health economics. Soc Sci Med. 2009;69(5):786–92.CrossRefPubMed Coast J. Maximisation in extra-welfarism: a critique of the current position in health economics. Soc Sci Med. 2009;69(5):786–92.CrossRefPubMed
3.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2005. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2005.
5.
go back to reference National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
6.
go back to reference Orford J. Power, powerlessness and addiction. Cambridge: Cambridge University Press; 2013. Orford J. Power, powerlessness and addiction. Cambridge: Cambridge University Press; 2013.
7.
go back to reference Sen A. Capability and well-being. The quality of life. Oxford: Oxford University Press; 1993. Sen A. Capability and well-being. The quality of life. Oxford: Oxford University Press; 1993.
8.
go back to reference Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–76.CrossRefPubMed Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–76.CrossRefPubMed
9.
go back to reference Goranitis I, Coast J, Day E, Copello A, Freemantle N, Seddon J, et al. Measuring health and broader well-being benefits in the context of opiate dependence: the psychometric performance of the ICECAP-A and the EQ-5D-5L. Value Health. 2016;19(6):820–8.CrossRefPubMed Goranitis I, Coast J, Day E, Copello A, Freemantle N, Seddon J, et al. Measuring health and broader well-being benefits in the context of opiate dependence: the psychometric performance of the ICECAP-A and the EQ-5D-5L. Value Health. 2016;19(6):820–8.CrossRefPubMed
10.
go back to reference Day E, Copello A, Seddon JL, Christie M, Bamber D, Powell C, et al. Pilot study of a social network intervention for heroin users in opiate substitution treatment: study protocol for a randomized controlled trial. Trials. 2013;14(1):264.CrossRefPubMedPubMedCentral Day E, Copello A, Seddon JL, Christie M, Bamber D, Powell C, et al. Pilot study of a social network intervention for heroin users in opiate substitution treatment: study protocol for a randomized controlled trial. Trials. 2013;14(1):264.CrossRefPubMedPubMedCentral
11.
go back to reference Day E, Copello A, Seddon JL, Christie M, Bamber D, Powell C, Bennett C, Akhtar S, George S, Ball A, Frew E, Goranitis I, Freemantle N. A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services. BMC Psychiatry. 2018;18(1):8.CrossRefPubMedPubMedCentral Day E, Copello A, Seddon JL, Christie M, Bamber D, Powell C, Bennett C, Akhtar S, George S, Ball A, Frew E, Goranitis I, Freemantle N. A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services. BMC Psychiatry. 2018;18(1):8.CrossRefPubMedPubMedCentral
12.
go back to reference Baio G. Bayesian methods in health economics. Chapman and Hall/CRC Press. Boca Raton, FL, US. 2012. Baio G. Bayesian methods in health economics. Chapman and Hall/CRC Press. Boca Raton, FL, US. 2012.
13.
go back to reference Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Health Qual Life Outcomes. 2015b;13(1):106.CrossRefPubMedPubMedCentral Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Health Qual Life Outcomes. 2015b;13(1):106.CrossRefPubMedPubMedCentral
14.
go back to reference Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed
15.
go back to reference Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. PharmacoEconomics. 2015a;33(10):993–1011.CrossRefPubMed Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. PharmacoEconomics. 2015a;33(10):993–1011.CrossRefPubMed
16.
go back to reference Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, et al. Towards a standardised brief outcome measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry. 2002 Jan;180:51–60.CrossRefPubMed Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, et al. Towards a standardised brief outcome measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry. 2002 Jan;180:51–60.CrossRefPubMed
17.
go back to reference Barkham M, Mellor-Clark J, Connell J, Cahill J. A CORE approach to practice-based evidence: a brief history of the origins and applications of the CORE-OM and CORE system. Couns Psychother Res. 2006;6(1):3–15.CrossRef Barkham M, Mellor-Clark J, Connell J, Cahill J. A CORE approach to practice-based evidence: a brief history of the origins and applications of the CORE-OM and CORE system. Couns Psychother Res. 2006;6(1):3–15.CrossRef
18.
go back to reference Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89(5):563–72.CrossRefPubMed Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89(5):563–72.CrossRefPubMed
19.
go back to reference Raistrick R, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89(5):563-572. Raistrick R, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89(5):563-572.
20.
go back to reference Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxburgh M, et al. Development of the treatment outcomes profile. Addiction. 2008;103(9):1450–60.CrossRefPubMed Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxburgh M, et al. Development of the treatment outcomes profile. Addiction. 2008;103(9):1450–60.CrossRefPubMed
22.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRefPubMedPubMedCentral Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRefPubMedPubMedCentral
23.
go back to reference Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England.. 2016. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England.. 2016.
24.
go back to reference Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, et al. Scoring the Icecap-a capability instrument. Estimation of a UK general population tariff. Health Econ. 2015;24(3):258–69.CrossRefPubMed Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, et al. Scoring the Icecap-a capability instrument. Estimation of a UK general population tariff. Health Econ. 2015;24(3):258–69.CrossRefPubMed
25.
go back to reference Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRefPubMed Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRefPubMed
26.
go back to reference Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427–34.CrossRefPubMed Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427–34.CrossRefPubMed
27.
go back to reference McKenzie L, Van Der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health. 2009;12(1):167–71.CrossRefPubMed McKenzie L, Van Der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health. 2009;12(1):167–71.CrossRefPubMed
28.
go back to reference Pinedo-Villanueva RA, Turner D, Judge A, Raftery JP, Arden NK. Mapping the Oxford hip score onto the EQ-5D utility index. Qual Life Res. 2013;22(3):665–75.CrossRefPubMed Pinedo-Villanueva RA, Turner D, Judge A, Raftery JP, Arden NK. Mapping the Oxford hip score onto the EQ-5D utility index. Qual Life Res. 2013;22(3):665–75.CrossRefPubMed
29.
go back to reference Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in healthcare. Oxford: OUP; 2010. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in healthcare. Oxford: OUP; 2010.
30.
go back to reference Mitchell PM, Roberts TE, Barton PM, Pollard BS, Coast J. Predicting the ICECAP-O capability index from the WOMAC osteoarthritis index: is mapping onto capability from condition-specific health status questionnaires feasible? Med Decis Mak. 2013;33(4):547–57.CrossRef Mitchell PM, Roberts TE, Barton PM, Pollard BS, Coast J. Predicting the ICECAP-O capability index from the WOMAC osteoarthritis index: is mapping onto capability from condition-specific health status questionnaires feasible? Med Decis Mak. 2013;33(4):547–57.CrossRef
31.
go back to reference Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683–94.CrossRefPubMed Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683–94.CrossRefPubMed
32.
go back to reference Skaltsa K, Longworth L, Ivanescu C, Phung D, Holmstrom S. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate Cancer. Value Health. 2014;17(2):238–44.CrossRefPubMed Skaltsa K, Longworth L, Ivanescu C, Phung D, Holmstrom S. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate Cancer. Value Health. 2014;17(2):238–44.CrossRefPubMed
33.
go back to reference Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Mak. 2006;26(4):401–9.CrossRef Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Mak. 2006;26(4):401–9.CrossRef
34.
go back to reference Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Mak. 2015;35(7):912–26.CrossRef Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Mak. 2015;35(7):912–26.CrossRef
35.
go back to reference Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Mak. 2010;30(3):341–54.CrossRef Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Mak. 2010;30(3):341–54.CrossRef
36.
go back to reference Khan KA, Madan J, Petrou S, Lamb SE. Mapping between the Roland Morris questionnaire and generic preference-based measures. Value Health. 2014;17(6):686–95.CrossRefPubMed Khan KA, Madan J, Petrou S, Lamb SE. Mapping between the Roland Morris questionnaire and generic preference-based measures. Value Health. 2014;17(6):686–95.CrossRefPubMed
37.
go back to reference Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.CrossRefPubMed Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.CrossRefPubMed
38.
go back to reference Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abus Treat. 2017;76:88–93.CrossRef Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abus Treat. 2017;76:88–93.CrossRef
39.
go back to reference Young MK, Ng S, Mellick G, Scuffham PA. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson’s disease. Qual Life Res. 2013;22(5):1065–72.CrossRefPubMed Young MK, Ng S, Mellick G, Scuffham PA. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson’s disease. Qual Life Res. 2013;22(5):1065–72.CrossRefPubMed
40.
go back to reference Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health. 2009;12(8):1151–7.CrossRefPubMed Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health. 2009;12(8):1151–7.CrossRefPubMed
41.
go back to reference Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of Cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12(1):180.CrossRefPubMedPubMedCentral Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of Cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12(1):180.CrossRefPubMedPubMedCentral
42.
go back to reference Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):vii,viii, xiii-xxv):1–188.CrossRefPubMedPubMedCentral Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):vii,viii, xiii-xxv):1–188.CrossRefPubMedPubMedCentral
43.
go back to reference Hawton A, Green C, Telford C, Wright D, Zajicek J. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler J. 2012;18(6):853–61.CrossRef Hawton A, Green C, Telford C, Wright D, Zajicek J. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler J. 2012;18(6):853–61.CrossRef
44.
go back to reference Kim H, Kim D, Jang EJ, Lee M, Song HJ, Park S, et al. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean observational study network for arthritis (KORONA) registry data. Rheumatol Int. 2016;36(4):505–13.CrossRefPubMed Kim H, Kim D, Jang EJ, Lee M, Song HJ, Park S, et al. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean observational study network for arthritis (KORONA) registry data. Rheumatol Int. 2016;36(4):505–13.CrossRefPubMed
45.
go back to reference Goranitis I, Coast J, Day E, Copello A, Freemantle N, Frew E. Maximizing health or sufficient capability in economic evaluation? A methodological experiment of treatment for drug addiction. Med Decis Mak. 2017;37(5):498–511.CrossRef Goranitis I, Coast J, Day E, Copello A, Freemantle N, Frew E. Maximizing health or sufficient capability in economic evaluation? A methodological experiment of treatment for drug addiction. Med Decis Mak. 2017;37(5):498–511.CrossRef
Metadata
Title
Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP
Authors
Jasmine Peak
Ilias Goranitis
Ed Day
Alex Copello
Nick Freemantle
Emma Frew
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-018-0926-7

Other articles of this Issue 1/2018

Health and Quality of Life Outcomes 1/2018 Go to the issue